论文部分内容阅读
雄性Wistar大鼠70只,随机平均分为7组,正常对照组,糖尿病对照组氨基胍(100mh/kg/d)治疗组和黄芩苷,葛根素,川芎嗪,水飞蓟素(150mh/kg/d)治疗组,腹腔注射链脲佐菌素(60mg/kg)诱发糖尿病。16周后,处死大鼠,分离肾脏,称重然后进行肾皮质糖基化终末产物(AGEs)测定。结果:治疗前后各组血糖无明显变化。治疗后糖尿病组双肾重量明显高于正常对照(P<0.01),5个治疗组双肾重量明显低于糖尿病组(P<0.01),各治疗组间无明显差异(P>0.05)。糖尿病AGEs含量明显高于正常对照(P<0.01),5个治疗组AGEs含量明显低于糖尿病组(P<0.01),各治疗组间无明显差异(P>0.05)结论:1.蛋白质非酶糖化生成AGEs参与DN的发生与发展。2.中药对非酶糖化的抑制作用与典型糖化抑制剂氨基胍相似,且价格低、副作用少,值得临床推荐应用。
70 male Wistar rats were randomly divided into 7 groups, normal control group, diabetic control group, aminoguanidine (100mh/kg/d) treatment group and baicalin, puerarin, ligustrazine, silymarin (150mh/kg/d). In the treatment group, diabetes was induced by intraperitoneal injection of streptozotocin (60 mg/kg). After 16 weeks, the rats were sacrificed, the kidneys were detached, weighed, and then renal cortical glycosylation end product (AGEs) assays were performed. Results: There was no significant change in blood glucose before and after treatment. After treatment, the weight of double kidney in diabetic group was significantly higher than that of normal control (P<0.01). The weight of double kidney in five treatment groups was significantly lower than that in diabetic group (P<0.01). There was no significant difference among the treatment groups (P>0.05). The level of AGEs in diabetes was significantly higher than that in normal controls (P<0.01). The content of AGEs in the five treatment groups was significantly lower than that in the diabetic group (P<0.01). There was no significant difference among the treatment groups (P>0.05). Conclusions: 1. Protein non-enzyme Glycation produces AGEs to participate in the occurrence and development of DN. 2. The inhibitory effect of traditional Chinese medicine on non-enzymatic saccharification is similar to the typical glycosylation inhibitor aminoguanidine, and its low price and few side effects are worthy of clinical application.